Inagaki Chiaki, Shimoi Tatsunori, Okuma Hitomi, Kitano Akiko, Shimomura Akihiko, Noguchi Emi, Kodaira Makoto, Yunokawa Mayu, Yonemori Kan, Shimizu Chikako, Yoshida Akihiko, Fujiwara Yasuhiro, Tamura Kenji
Departments of Breast and Medical Oncology.
Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan.
Anticancer Drugs. 2018 Jan;29(1):97-101. doi: 10.1097/CAD.0000000000000558.
Eribulin mesylate (eribulin) is a nontaxane microtubule inhibitor approved in Japan for treating soft tissue sarcoma irrespective of histological subtypes. Thus, our department routinely uses eribulin to treat any histological subtype of sarcoma for patients who have experienced disease progression during standard therapy. However, evidence on the efficacy of eribulin in treating sarcomas that are neither liposarcoma nor leiomyosarcoma is limited. Recently, we encountered a case of a heavily pretreated cardiac angiosarcoma that responded well to eribulin treatment. The patient was a 34-year-old Japanese woman with advanced angiosarcoma, who had been pretreated heavily using several lines of chemotherapy. Eribulin was administered as the eighth line of treatment and the dose was adjusted because of grade 4 neutropenia. After three cycles of treatment, contrast-enhanced computed tomography showed a partial tumor response, which was sustained for ~4 months. This case suggests that eribulin may be a potential therapeutic option for angiosarcoma. Further studies are needed to confirm the benefit of eribulin for patients with angiosarcoma and to establish predictive markers for eribulin sensitivity.
甲磺酸艾瑞布林（艾瑞布林）是一种非紫杉烷类微管抑制剂，在日本被批准用于治疗软组织肉瘤，无论其组织学亚型如何。因此，我们科室常规使用艾瑞布林治疗标准治疗期间病情进展的肉瘤患者的任何组织学亚型。然而，关于艾瑞布林治疗既非脂肪肉瘤也非平滑肌肉瘤的肉瘤疗效的证据有限。最近，我们遇到了一例经过大量预处理的心脏血管肉瘤患者，其对艾瑞布林治疗反应良好。该患者是一名34岁的日本女性，患有晚期血管肉瘤，此前已接受多线化疗进行大量预处理。艾瑞布林作为第八线治疗药物给药，并因4级中性粒细胞减少症调整了剂量。经过三个周期的治疗，增强计算机断层扫描显示肿瘤部分缓解，持续约4个月。该病例表明艾瑞布林可能是血管肉瘤的一种潜在治疗选择。需要进一步研究以证实艾瑞布林对血管肉瘤患者的益处，并建立艾瑞布林敏感性的预测标志物。
